A new and sensitive method for the quantification of HBV cccDNA by real-time PCR

被引：75

作者：

He, ML ^{[1
]}

Wu, J

Chen, Y

Lin, MC

Lau, GKK

Kung, HF

机构：

[1] Inst Mol Technol Drug Discovery & Synth, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China

[2] Inst Mol Technol Drug Discovery & Synth, Open Lab, Hong Kong, Hong Kong, Peoples R China

[3] Shanghai Inst Plant Physiol & Ecol, Shanghai, Peoples R China

[4] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2002年 / 295卷 / 05期

关键词：

hepatitis B virus; HBV cccDNA; quantitative PCR; HBV quantification;

D O I：

10.1016/S0006-291X(02)00813-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The persistence of covalently closed circular (ccc) DNA of Hepatitis B virus (HBV) in liver cells is believed to be the major reason for relapse after completion of HBV antiviral therapy. Up to now, there is no sensitive method to quantify cccDNA in infected liver cells. We designed a set of primers to specifically amplify DNA fragments from HBV cccDNA but not from viral genomic DNA. A good linear range was obtained when 100-10(7) copies of HBV cccDNA were used as template in the quantitative real-time PCR. Not only is this method rapid, economical, highly sensitive, it can be used to monitor HBV cccDNA in infected human liver biopsies and to guide patients undergoing long-term anti-HBV therapy. (C) 2002 Elsevier Science (USA). All rights reserved.

引用

页码：1102 / 1107

页数：6

共 28 条

[1] A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta
Asahina, Y
Izumi, N
Uchihara, M
Noguchi, O
Tsuchiya, K
Hamano, K
Kanazawa, N
Itakura, J
Miyake, S
Sakai, T
[J]. HEPATOLOGY, 2001, 34 (02) : 377 - 384
[2] Ausubel FM., 1998, CURRENT PROTOCOLS MO
[3] Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR
Damond, F
Descamps, D
Farfara, I
Telles, JN
Puyeo, S
Campa, P
Leprêtre, A
Matheron, S
Brun-Vezinet, F
Simon, F
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) : 4264 - 4268
[4] REVERSION OF DUCK HEPATITIS-B VIRUS-DNA REPLICATION IN-VIVO FOLLOWING CESSATION OF TREATMENT WITH THE NUCLEOSIDE ANALOG GANCICLOVIR
DEAN, J
BOWDEN, S
LOCARNINI, S
[J]. ANTIVIRAL RESEARCH, 1995, 27 (1-2) : 171 - 178
[5] FU L, 1997, CHIN J VIROL, V13, P216
[6] Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
Hance, AJ
Lemiale, V
Izopet, J
Lecossier, D
Joly, V
Massip, P
Mammano, F
Descamps, D
Brun-Vézinet, F
Clavel, F
[J]. JOURNAL OF VIROLOGY, 2001, 75 (14) : 6410 - 6417
[7] Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay
Jardi, R
Rodriguez, F
Buti, M
Costa, X
Cotrina, M
Valdes, A
Galimany, R
Esteban, R
[J]. JOURNAL OF VIRAL HEPATITIS, 2001, 8 (06) : 465 - 471
[8] Molecular approaches to validate disinfectants against human hepatitis B virus
Jursch, CA
Gerlich, WH
Glebe, D
Schaefer, S
Marie, O
Thraenhart, O
[J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2002, 190 (04) : 189 - 197
[9] Quantitation of HCV RNA using real-time PCR and fluorimetry
Komurian-Pradel, F
Paranhos-Baccalà, G
Sodoyer, M
Chevallier, P
Mandrand, B
Lotteau, V
André, P
[J]. JOURNAL OF VIROLOGICAL METHODS, 2001, 95 (1-2) : 111 - 119
[10] Ladner SK, 1998, ANTIVIR CHEM CHEMOTH, V9, P65

← 1 2 3 →